| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/15/2009 | CA2400155C A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor |
| 09/15/2009 | CA2389163C Process for the production of antiulceratives |
| 09/15/2009 | CA2372560C Cyanopyrroles for binding the progesterone receptor |
| 09/15/2009 | CA2366514C Diagnostic and therapeutic use of antibodies against the urokinase receptor |
| 09/15/2009 | CA2323111C New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions |
| 09/15/2009 | CA2218699C 1,3-propane diol derivatives as bioactive compounds |
| 09/14/2009 | CA2625811A1 Microrna mediated oncolytic targeting |
| 09/11/2009 | WO2009111698A1 Improved anticancer treatments |
| 09/11/2009 | WO2009111653A2 Antiviral therapeutic agents |
| 09/11/2009 | WO2009111648A1 Compositions and methods for mucositis and oncology therapies |
| 09/11/2009 | WO2009111607A1 Hydroxyalkanyl amides as modulators of chemokine receptor activity |
| 09/11/2009 | WO2009111555A1 Combination treatment for bladder cancer comprisining valrubicin and trospium chloride |
| 09/11/2009 | WO2009111547A1 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| 09/11/2009 | WO2009111531A1 Pyrrolotriazine kinase inhibitors |
| 09/11/2009 | WO2009111508A2 Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| 09/11/2009 | WO2009111375A2 Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas |
| 09/11/2009 | WO2009111280A1 N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| 09/11/2009 | WO2009111279A1 Pyrazole [3, 4-b] pyridine raf inhibitors |
| 09/11/2009 | WO2009111277A1 Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| 09/11/2009 | WO2009111271A1 Polymer paclitaxel conjugates and methods for treating cancer |
| 09/11/2009 | WO2009111085A1 Use of cd23 antibodies to treat malignancies in patients with poor prognosis |
| 09/11/2009 | WO2009111028A1 Aurora kinase inhibitors |
| 09/11/2009 | WO2009110546A1 Composition containing aqueous extract of ashwaganda leaves as the active ingredient and method of producing the same |
| 09/11/2009 | WO2009110495A1 Promoter for secretion of insulin-like growth factor-1, and food or beverage containing the same |
| 09/11/2009 | WO2009110416A1 Concomitant drug |
| 09/11/2009 | WO2009110415A1 Concomitant drug |
| 09/11/2009 | WO2009110383A1 Method for screening of therapeutic agent for cancer |
| 09/11/2009 | WO2009110324A1 Method for regulation of expression of low-density lipoprotein receptor, and enhancer of expression of low-density lipoprotein receptor |
| 09/11/2009 | WO2009110235A1 Combined use of cholestanol derivative |
| 09/11/2009 | WO2009110041A1 Cancer therapeutic agent by agent for cancer-specific introduction of prostacyclin receptor antagonist |
| 09/11/2009 | WO2009110007A1 Spiro derivatives of parthenin as novel anticancer agents |
| 09/11/2009 | WO2009110000A1 Novel napthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof |
| 09/11/2009 | WO2009109986A1 Chalcone linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof |
| 09/11/2009 | WO2009109984A1 Quinazoline linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof' |
| 09/11/2009 | WO2009109927A2 Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer |
| 09/11/2009 | WO2009109867A2 Crystal form of phenylamino pyrimidine derivatives |
| 09/11/2009 | WO2009109862A2 Improved cancer therapeutics |
| 09/11/2009 | WO2009109861A1 Methods of treatment employing prolonged continuous infusion of belinostat |
| 09/11/2009 | WO2009109855A2 Immunotherapy for unresectable pancreatic cancer |
| 09/11/2009 | WO2009109679A1 Use of virgin olive oil polyphenolic compounds in cancer treatment |
| 09/11/2009 | WO2009109605A1 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 09/11/2009 | WO2009109576A1 Pim kinase inhibitors and methods of their use |
| 09/11/2009 | WO2009109388A1 Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation |
| 09/11/2009 | WO2009109356A1 Cytostatic compositions |
| 09/11/2009 | WO2009109230A1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| 09/11/2009 | WO2009109146A1 Use of hepatocyte nuclear factor 4α(hnf4α) for the treatment of human malignant solid tumors through induction-differentiation therapy |
| 09/11/2009 | WO2009109109A1 Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors |
| 09/11/2009 | WO2009109071A1 Imidazopyridine compounds |
| 09/11/2009 | WO2009109029A1 Diquinolonium salt for the treatment of cancer |
| 09/11/2009 | WO2009081275A3 Antifolate compounds for the treatment of melanoma |
| 09/11/2009 | WO2009055506A9 Aminoflavone (nsc 686288) and combinations thereof for treating breast cancer |
| 09/11/2009 | WO2009055074A3 Erbb2 binding proteins and use thereof |
| 09/11/2009 | WO2009040069A3 Use of bq-610 alone or in combination with helodermin as a therapeutic agent |
| 09/11/2009 | WO2009038701A3 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
| 09/11/2009 | WO2009034136A3 Pharmaceutical compound |
| 09/11/2009 | WO2009033821A3 Use of a peptide as a therapeutic agent |
| 09/11/2009 | WO2009033779A3 Nociceptin for use as a therapeutic agent |
| 09/11/2009 | WO2009033778A3 Mage-3 antigen and others for use as a therapeutic agent |
| 09/11/2009 | WO2009033775A3 Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent |
| 09/11/2009 | WO2009033732A3 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent |
| 09/11/2009 | WO2009033729A3 Therapeutic uses of gastrin- 1 and g- pen-grgdspca |
| 09/11/2009 | WO2009033726A3 Use of cart (55-102), optionally in combination with tuftsin, as a therapeutic agent |
| 09/11/2009 | WO2009033683A3 Galanin message associated peptide alone or in combination with minigastrin as a therapeutic agent |
| 09/11/2009 | WO2009030065A8 INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION |
| 09/11/2009 | WO2009026446A3 Hdac inhibitors |
| 09/11/2009 | WO2008078109A3 Medicament |
| 09/11/2009 | WO2007026190A9 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| 09/11/2009 | CA2728855A1 Spiro derivatives of parthenin as novel anticancer agents |
| 09/11/2009 | CA2717803A1 Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| 09/11/2009 | CA2717511A1 Modulation of enzymatic structure, activity, and/or expression level |
| 09/11/2009 | CA2717409A1 Improved anticancer treatments |
| 09/11/2009 | CA2717388A1 Pim kinase inhibitors and methods of their use |
| 09/11/2009 | CA2717207A1 Methods of treatment employing prolonged continuous infusion of belinostat |
| 09/11/2009 | CA2717173A1 Antiviral therapeutic agents |
| 09/11/2009 | CA2717135A1 Combined use of cholestanol derivative |
| 09/11/2009 | CA2716952A1 Pyrazole [3,4-b] pyridine raf inhibitors |
| 09/11/2009 | CA2716951A1 Raf inhibitor compounds and methods of use thereof |
| 09/11/2009 | CA2716949A1 N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| 09/11/2009 | CA2716947A1 Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| 09/11/2009 | CA2716851A1 Combination therapy with c-met and egfr antagonists |
| 09/11/2009 | CA2716767A1 Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
| 09/11/2009 | CA2716518A1 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| 09/11/2009 | CA2716413A1 Crystal form of phenylamino pyrimidine derivatives |
| 09/11/2009 | CA2716354A1 Contrast agents for applications including perfusion imaging |
| 09/11/2009 | CA2715796A1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| 09/11/2009 | CA2714441A1 Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation |
| 09/10/2009 | US20090227795 Target molecules of pladienolides, compounds binding to such target molecules, and screening method thereof |
| 09/10/2009 | US20090227681 Polymorphic form of n-(s)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl) cyclopropane-1-sulfonamide and uses thereof |
| 09/10/2009 | US20090227676 Methods and compositions for treating cancer |
| 09/10/2009 | US20090227674 Combination methods fo saha and targretin for treating cancer |
| 09/10/2009 | US20090227662 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 09/10/2009 | US20090227655 Nonviral vectors for delivering polynucleotides to target tissue |
| 09/10/2009 | US20090227652 Indole derivatives and methods of using the same |
| 09/10/2009 | US20090227650 Novel crystalline forms of Lestaurtinib |
| 09/10/2009 | US20090227648 Pyrazole derivatives useful for the treatment of cancer |
| 09/10/2009 | US20090227641 Cycloalkylamino acid derivatives |
| 09/10/2009 | US20090227633 Methods to inhibit tumor cell growth by using proton pump inhibitors |
| 09/10/2009 | US20090227630 Pharmaceutical Composition Achieving Excellent Absorbency of Pharmacologically Active Substance |
| 09/10/2009 | US20090227619 Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo |
| 09/10/2009 | US20090227616 Inhibitors of akt activity |